SHORT MINI FUTURE - MODERNA | Market Closed - Swiss Exchange 08:50:00 10/05/2024 pm IST | ||
| 0.93 CHF | +1.09% |
|
| Current month | -7.92% | ||
| 1 month | -11.43% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/24/10 | 0.93 | +1.09% | 0 |
| 08/24/08 | 0.92 | -2.13% | 0 |
| 06/24/06 | 0.94 | +4.44% | 0 |
| 03/24/03 | 0.9 | -5.26% | 0 |
| 02/24/02 | 0.95 | -5.94% | 0 |
Delayed Quote Swiss Exchange
Last update May 10, 2024 at 08:50 pm IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | Bank Julius Bär |
| LMRAJB | |
| ISIN | CH1242072689 |
| Date issued | 06/01/2023 |
| Strike | 219.5 $ |
| Maturity | Unlimited |
| Parity | 100 : 1 |
| Emission price | - CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 1.37 CHF |
|---|---|
| Lowest since issue | 0.12 CHF |
| Spread | 0.01 CHF |
| Spread % | 1.06% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
117.3
USD
Average target price
139.4
USD
Spread / Average Target
+18.79%
- Stock Market
- Certificates
- LMRAJB Certificat